Id: | acc4011 |
Group: | 1sens |
Protein: | STAT1 |
Gene Symbol: | STAT1 |
Protein Id: | P42224 |
Protein Name: | STAT1_HUMAN |
PTM: | phosphorylation |
Site: | Tyr701 |
Site Sequence: | ELDGPKGTGYIKTELISVSEV |
Disease Category: | Digestive system diseases |
Disease: | Chronic Hepatitis C |
Disease Subtype: | |
Disease Cellline: | cynomolgus monkey hepatocytes |
Disease Info: | |
Drug: | pegIFNlambda |
Drug Info: | PegIFNlambda is a drug. It may be used in certain medical treatments. |
Effect: | modulate |
Effect Info: | Pegylated interferon lambda - 1 (pegIFNλ) induces the expression of interferon - stimulated genes (ISG) by selectively activating the phosphorylation of STAT1 in hepatocytes. |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 22280056 |
Sentence Index: | 22280056_2 |
Sentence: | "A pegylated human IFN lambda-1 (pegIFNlambda) is under development for chronic hepatitis C. Induction of receptor signaling (STAT1 phosphorylation) and expression of interferon-stimulated genes (ISGs) by pegIFNlambda were assessed in, respectively, cynomolgus monkey leukocyte subsets and hepatocytes stimulated in vitro." |
Sequence & Structure:
MSQWYELQQLDSKFLEQVHQLYDDSFPMEIRQYLAQWLEKQDWEHAANDVSFATIRFHDLLSQLDDQYSRFSLENNFLLQHNIRKSKRNLQDNFQEDPIQMSMIIYSCLKEERKILENAQRFNQAQSGNIQSTVMLDKQKELDSKVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETNGVAKSDQKQEQLLLKKMYLMLDNKRKEVVHKIIELLNVTELTQNALINDELVEWKRRQQSACIGGPPNACLDQLQNWFTIVAESLQQVRQQLKKLEELEQKYTYEHDPITKNKQVLWDRTFSLFQQLIQSSFVVERQPCMPTHPQRPLVLKTGVQFTVKLRLLVKLQELNYNLKVKVLFDKDVNERNTVKGFRKFNILGTHTKVMNMEESTNGSLAAEFRHLQLKEQKNAGTRTNEGPLIVTEELHSLSFETQLCQPGLVIDLETTSLPVVVISNVSQLPSGWASILWYNMLVAEPRNLSFFLTPPCARWAQLSEVLSWQFSSVTKRGLNVDQLNMLGEKLLGPNASPDGLIPWTRFCKENINDKNFPFWLWIESILELIKKHLLPLWNDGCIMGFISKERERALLKDQQPGTFLLRFSESSREGAITFTWVERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAENIPENPLKYLYPNIDKDHAFGKYYSRPKEAPEPMELDGPKGTGYIKTELISVSEVHPSRLQTTDNLLPMSPEEFDEVSRIVGSVEFDSMMNTV
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
Y | 701 | D | Melanoma | Phosphorylation | 17785551 |
Y | 701 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 24058806 |
Y | 701 | U | Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome | Phosphorylation | 33815425 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMProtein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
---|---|---|---|---|---|---|---|---|---|
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -0.6427 | down | |
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -1.7733 | - | |
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -0.8673 | - | |
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -3.5049 | - | |
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -1.2234 | - | |
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -3.8772 | - | |
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -2.9951 | - | |
P42224 | STAT1 | P | Tyr701 | GTGY(ph)IK | ARH-77 | Rituximab | -1.6009 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.